Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096244 | 0.86 | THRB (0.36) | THRBLMNAFPR2PKMALDH1A1 | |
| SCHEMBL13096254 | 0.85 | THRB (0.33) | THRBLMNAFPR2PKMHTT | |
| SCHEMBL13288550 | 0.84 | KMT2A (0.34) | THRBLMNAL3MBTL1MAPTKDM4E | |
| SCHEMBL14490563 | 0.82 | KMT2A (0.31) | THRBLMNAKMT2A | |
| SCHEMBL14372094 | 0.82 | ACACB (0.38) | ACHE | |
| SCHEMBL13071297 | 0.82 | LMNA (0.35) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13244221 | 0.81 | KMT2A (0.30) | KMT2A | |
| SCHEMBL13096258 | 0.79 | THRB (0.33) | THRBHTT | |
| SCHEMBL13096248 | 0.78 | ACACB (0.39) | THRBLMNAFPR2PKMALDH1A1 | |
| SCHEMBL13096247 | 0.78 | ACACB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383853-B2 | Method for preparing 2,6-diethyl-4-methylphenylacetic acid | BAYER CROPSCIENCE AG (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383853-B2 | Method for preparing 2,6-diethyl-4-methylphenylacetic acid | BAYER CROPSCIENCE AG (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20100261934-A1 | Method for Preparing 2,6-Diethyl-4-Methylphenylacetic Acid | BAYER CROPSCIENCE AG (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261934-A1 | Method for Preparing 2,6-Diethyl-4-Methylphenylacetic Acid | BAYER CROPSCIENCE AG (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2218710-A1 | Procedure for the preparation of 2,6-diethyl-4-methylphenylacetic acid | Bayer CropScience AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20080318776-A1 | 2,6-Diethyl-4-Methylphenyl-Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318776-A1 | 2,6-Diethyl-4-Methylphenyl-Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261934-A1 | Method for Preparing 2,6-Diethyl-4-Methylphenylacetic Acid | DDT, TET1, DDC | THRB 754/4885LMNA 4009/4885FPR2 4596/4885 |
| US-20080318776-A1 | 2,6-Diethyl-4-Methylphenyl-Substituted Tetramic Acid Derivatives | DDT, TET1, TET3 | THRB 288/4885LMNA 4223/4885FPR2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.